health reform

Healthcare Monitoring – Fast Company Market Perspectives

Healthcare Monitoring – Fast Company -“Why We Don’t Talk About “Wearable Software”

Revolution is coming in the wearable healthcare monitoring arena as we move from devices to software/ ecosystems and new predictive analytics are fully embraced. Excellent Fast Company Labs article by Tina Amirtha summarizing directions. I see significant opportunity here not covered in the article  – why pharmas will play a key role, role of wearables in telemonitoring/Telehealth, tracking medication compliance,adverse drug reactions. And wearable healthcare monitoring coupled with analytics is spawning many exciting entrepreneurial ventures

Check out the Fast Company article at http://tinyurl.com/klzncnl. My comments shown are shortened due to space – here is a complete copy:

Tina- great article. As former CEO of a public predictive analytics company pleased to share comments. First, analytics is indeed the “Holy Grail” but my view is the real opportunity drivers here are not individuals but pharmas who have the incentive to establish and grow ongoing patient relationships. Healthcare monitoring/analytics is ideal strategy to help pharmas achieve this objective. Last time I looked the 3 to 4 major pharma chains represent about $200 billion or 75 percent of the market and about 24,000 locations- independent pharmas account for the rest of the locations and market. Secondly, health monitoring devices can make a substantive contribution to Telehealth/ telemedicine – I have done work in this area and telemonitoring proponents have not fully embraced these technologies- in my view and they are missing a real opportunity. We are seeing new entrepreneurial ventures addressing this market- my experience is creating sustainable business models addressing hardware, software, analytics dimensions is a real challenge for some of the reasons you noted.

Finally, in a late 2012 blog post “Buy Health Monitoring Devices Off The Clothing Rack      http://tinyurl.com/nhyp9uy 
I suggested we may be buying health care monitors in Lands End, and discussed how this will impact traditional retailer strategies. Sales staff questions may move from “What size and color jacket would you like to see?” to “Can I show you our blood pressure-only monitoring jacket or our top of the line full featured model tracking glucose, oxygenation and includes a USB port?”And what about health care coverage. Expect to see some interesting issues emerge here- are you buying a jacket or a medical device; where do you draw the line? Clothing may also be an external driver to grow this market

Bottom line here- the real opportunity, which translates into hard dollar cost savings and improved healthcare quality, is using wearables and the software ecosystem to track medication compliance, adverse drug reactions, drug efficacies, and similar data. My vision is coupling wearable healthcare monitors with predictive analytics will dramatically reshape today’s healthcare system- refocusing the emphasis of today ‘ s wearable discussion and educating industry players on the possibilities here are the challenges and next steps needed to make this happen

Paul B. Silverman

 

Paul B. Silverman writes about entrepreneurship, healthcare, analytics, and strategy management and serves as Advisor, Speaker, Educator, and Managing Partner of the Gemini Business Group, LLC, a new venture development firm, and author of “8 Building Blocks To Launch, Manage, And Grow A Successful Business.” He also serves as Adjunct Professor in the School of Business at George Mason University. See more at Paul B. Silverman Blog and sign up for Entrepreneurship Today! email updates to track latest new venture developments.

 

Tagged , , , , , , , , , , , ,

Posted Comments on WSJ Article-“Can Data From Your Fitbit Transform Medicine?”

Posted comments on June 23rd WSJ Technology article addressing telemedicine – I follow this area and emphasized need to do more to develop telemedicine in the United States

We lag most developed countries in the telemedicine arena which reduces the quality of our healthcare system and increases costs

You can see the WSJ article and my comments at

http://online.wsj.com/articles/health-data-at-hand-with-trackers-1403561237?mod=djem10point

Here is a copy of comments I posted:

A winning formula- integrate telemedicine into patient’s EHRs. Mayo Clinic problems shows challenges. We are going in the wrong direction here. Three strategies to fully leverage telemedicine:1.Establish standards integrating remote monitoring devices with EHRs. The ACA ensures ‘meaningful use’ of EHRs. Well defined standards jumpstarts the remote health monitoring market moving from niche focus  2. Use analytics to emphasize benefits. Powerful analytics assess health issues and develop optimized treatment plans. For what is emerging, check out comments I posted on a healthsystemCIO.com site Posting HealthSystemsCIO.com. 3. Pro-actively address security concerns. “Tops down” national initiative emphasizing benefits- prenatal care, chronic conditions, improved outcomes particularly in rural areas with 25% of population but only 10% of physicians. Need to counter serious security concerns. e.g., April 26th guidelines from the Federation of State Medical Boards which can hamper growth.

Paul B. Silverman

 

Paul B. Silverman writes about entrepreneurship, healthcare, analytics, and strategy management and serves as Advisor, Speaker, Educator, and Managing Partner of the Gemini Business Group, LLC, a new venture development firm, and author of “8 Building Blocks To Launch, Manage, And Grow A Successful Business.” He also serves as Adjunct Professor in the School of Business at George Mason University. See more at Paul B. Silverman Blog and sign up for Entrepreneurship Today! email updates to track latest new venture developments.

 

Tagged , , , , , ,

Comments- Are Analytics Shifting from Executives to Employees?

Interesting article in Information Management Feb 6th issue  discussing how analytics decisions are being driven by mid-level staff rather than C-level executives. But analytics demands resources- what analytics should be pursued; how should analytics be deployed to increase revenue, decrease costs, and improve strategic position; what are the company’s key competitive peer group metrics? These are C-level not middle management decisions. Analytics, effectively deployed, can provide high ROI, but successful adoption typically demands C-level participation.

My comments noted no question there is a C-level gap in in understanding how analytics drives increased revenue, decreased costs, and improved strategic position. The concept of “analytics competitor,” mentioned in Tom Davenport’s writings (Competing on Analytics, others) emphasize that “C-level” analytics, creatively applied, helps companies create winning strategies- examples which I have used in MBA courses are Netflix, Progressive, and even Cirque du Soleil which created a new ‘circus/theater’ market sector- if you wonder why you don’t see three circus rings or elephants, analytics played a key role in these and many other decisions. Worthwhile reading. Key point- C-level management teams that understand the power of analytics driving new business strategy will achieve above average returns and a competitive edge. “Tops-down” thinking and unfortunately missed by many.

Secondly, no doubt there is a ‘massive treasure trove of data’ available- big data is a resource, not a solution. Analytics are the tool to leverage ‘big data” to improve key metrics, e.g., revenue, costs, strategic position, and so on. And no doubt analytics supports and improves workforce operational decisions… Read more including perspectives on analytics in the healthcare sector at http://tinyurl.com/mw674t8

 

Paul B. Silverman writes about entrepreneurship, healthcare, analytics, and strategy management and serves as Advisor, Speaker, Educator, and Managing Partner of the Gemini Business Group, LLC, a new venture development firm, and author of “8 Building Blocks To Launch, Manage, And Grow A Successful Business.” He also serves as Adjunct Professor in the School of Business at George Mason University. See more at Paul B. Silverman Blog and sign up for Entrepreneurship Today! email updates to track latest new venture developments.

Tagged , , , ,

Good Analytics Article- “…Reaping Returns from Analytics”

Good insightful article in the October 18, 2013 issue of Information Management on analytics by Narendra Mulani who is Managing Director of Accenture Analytics. I posted comments sharing some additional perspectives and related opportunities I foresee. One clear message here- the analytics market is positioned for major growth and as I noted in my comment related to healthcare analytics, today we are only seeing the ‘tip of the iceberg’ in this sector.

Check out at http://tinyurl.com/nyrd8q2

Here is a copy of the comments I posted:

Excellent article. I am pleased to share some comments based on my experience in the analytics arena.

Analytics clearly provide powerful tools to optimize business processes and value chain functions. What is often overlooked is understanding the impact of external and industry factors critical to maximize performance and mitigate risk. Some studies, for example, show that external factors have a 45 percent impact on ROA. Ignore these, and your analytics may address only 55 percent of the critical performance and risk drivers.

How will global environmental policies impact your business; what is impact of changing healthcare regulations on new drug development and clinical trials; what new market opportunities are projected based on disruptive innovation in your business; how will privacy and transborder data restrictions impact your business today and tomorrow. These are external drivers which can create new markets and ‘destroy’ existing ones.

Addressing how the external environment impacts your business demands analytics addressing STEEP analysis, Porter’s Five Forces, Peer Group modeling, and similar diagnostics. And these are not static analyses- change is the only constant in today’s global environment, and having current data is critical. The winning formula- couple traditional external analysis tools, such as STEEP, with unstructured exogenous data analytics provides dynamic, real time insights on external market and business portfolio impact. Integrate these insights with internal data analytics to develop ‘actionable’ analytics. Today’s fiercely competitive global markets demands this analytics rigor.

One interesting statistic suggests 85 percent of today’s analytics solutions address CRM applications, improving the performance and operations dealing with customers and related supply chain activities. The remaining 15 percent are emerging exciting analytics directions that offer exciting opportunities.

For example, in the legal arena, Technology-Assisted Review or “TAR”, uses computer models, machine learning, and analytics to sort millions of documents identifying relevant and privileged documents to support litigation with dramatic cost savings. TAR technologies are rapidly evolving and the acceptance of TAR is now being tested in state and Federal courts.

Analytics will also play an expanded role in traditional corporate strategy management. Fortune 500 companies have thousands of business portfolios often managed using traditional analytics, e.g., hurdle rates, IRR, others. Understanding with precision how these individual portfolios align with the Company’s overall strategic plan, what are the overall projection risks, where are the corporate exposures based on both internal and external factors, are the exciting new directions being pursued by leading edge companies.

While analytics applications in healthcare are accelerating, we are at the tip of the iceberg. Using machine learning to optimize clinical care and reduce longitudinal costs for patient care; integrating healthcare claims data, EHR and genomic data to evaluate patient outlook for both clinical and insurance applications; tracking and analyzing medications and vital signs to assess drug efficacy and adverse effects for drug trial screening; are some of the many exciting new directions we see emerging that will redefine today’s healthcare system improving both quality and cost performance.

Senior management will be challenged to understand these new analytics applications to improve their global performance and mitigate risk. Even business schools must adapt- new analytics tools are reshaping our traditional approach to strategy development and competitive analysis.

Clearly exciting times lie ahead for all players in the global analytics market

Paul B. Silverman writes about entrepreneurship, healthcare, analytics, and strategy management and serves as Advisor, Speaker, Educator, and Managing Partner of the Gemini Business Group, LLC, a new venture development firm, and author of “8 Building Blocks To Launch, Manage, And Grow A Successful Business.” He also serves as Adjunct Professor in the School of Business at George Mason University. See more at Paul B. Silverman Blog and sign up for Entrepreneurship Today! email updates to track latest new venture developments.

Paul B. Silverman

Tagged , , , , , , , ,

THE ‘SUGGESTIVE’ VS. ‘PREDICTIVE’ ANALYTICS ISSUE

I posted comments on the HealthCIO.com site in response to article suggesting ‘suggestive’ rather than ‘predictive’ analytics (“PA”) provides real, demonstrable benefits and that, rather than PA,  should be today’s primary focus. My point is with the proper vision and commitments here, PA tools offer powerful, exciting new tools to improve health care, both from patient care and financial perspective, reducing claims fraud and improving processes.And these same tools are spawning exciting new ‘analytics-centric’ ventures which I see as a high potential new venture sector and is one of my focus areas.

You can visit the HealthCIO.com site to see the original article “A Suggestion About Predictive Analytics” at http://tinyurl.com/7nw6twd and also see a reply to my comments. Copy of my comments follows:

Paul says:

‘SUGGESTIVE’ AND ‘PREDICTIVE’ ANALYTICS WILL BOTH HELP IMPROVE HEALTH CARE
Thanks for sharing your insights. As a former CEO of a predictive analytics company, and currently leading a new ‘analytics-centric’ leading edge, personal health and wellness company, among other activities, I am pleased to also contribute my perspectives here.
I like your idea of contrasting Suggestive vs. Predictive Analytics- there is obvious proven benefit in using analytics to improve quality at the point of patient care.
With regard to predictive analytics, I am pleased to offer comments:
–Predictive analytics is often muddled in with other statistical tools as you say, it is often difficult to appreciate and understand just how powerful these tools are and what is their specific contribution
–Rather than saying there are two flavors of PA, “easy and hard”, I suggest a better approach is to say there are two PA target opportunity areas in health care (and also in other sectors):
— Using PA to analyze the “known unknowns” – all of the patient treatment enhancements you described fall into this category- addressing known issues and processes, using analytics to improve processes, quality of care, and doing this more efficiently and at lower cost.
—Using PA to analyze the “unknown unknowns” – this is the real and power of predictive analytics and I believe really offers high upside for all health care players, and patients as well
–Look at the magnitude of today’s health care issues. As one example, increasing complexity of medication regimens used by patients, coupled with a fragmented health care system involving multiple prescribers, has made the occurrence of serious drug-drug interactions more likely today than ever before. For example, one study suggests Preventable Adverse Drug Events injure 1.5 million people a year, costs the U.S. healthcare system $3.5 billion and resulting in an estimated 44,000 to 98,000 deaths every year. Some studies show even higher numbers.
–Our aging population exacerbates the above issues. Studies show 41 percent of seniors take
5 or more prescription medications, and more than half has 2 or more prescribing physicians. And 24 percent- about 1 out of 4 – seniors having 3 or more chronic conditions have not shared information with their health care providers during the last 12 months. No wonder medication errors among seniors on Medicare are estimated at almost $900 million.

–We can use the real power of PA to better understand the “unknown-unknown” drivers here that are impacting our health care system, and create powerful new tools, improved processes and do this more efficiently while improving patient care.

–The “unknown-unknown” data I would like to see addresses questions such as why do we have adverse drug events; what are the rules we should be looking at and changing to reduce these events save lives, and reduce health costs; what are the underlying drivers and patterns for adverse drug events- do these vary by geography, treatment modalities, user demographics, specific types of medical facilities, maybe how and where medical practitioners are trained. “Unknown-unknowns” may, for example, identify certain treatment modalities and drug regimens used by select groups of medical professionals which drive adverse drug events. Predictive analytics, an inductive rather than deductive process, offers a powerful tool to help us identify these and many other critical underlying health care drivers.

I agree there are many PA projects that today may seem academic, but I do see great possibilities to improve our health care system, using powerful new predictive analytics computing tools and platforms coupled with more traditional analytics (both suggestive and deductive ‘rule based’ analytics), to dramatically improve the quality of our health care system. These new analytics and tools will address clinical issues such as the growing problem of adverse drug events, as well as addressing Medicare and other health care claims fraud and errors.

We are making progress, but I still believe we can be doing much more to achieve significant improvement in our nation’s health care system and very clear to me predictive analytics and other tools, with the proper vision and commitments, will play a substantive role.

Paul B. Silverman writes about entrepreneurship, healthcare, analytics, and strategy management and serves as Advisor, Speaker, Educator, and Managing Partner of the Gemini Business Group, LLC, a new venture development firm, and author of “8 Building Blocks To Launch, Manage, And Grow A Successful Business.” He also serves as Adjunct Professor in the School of Business at George Mason University. See more at Paul B. Silverman Blog and sign up for Entrepreneurship Today! email updates to track latest new venture developments.

 

v. is what we need to focus on to improve health care

Tagged , , , , , , ,

Entrepreneurship in the Health Care Sector and Syndicated National Radio Interview – Entrepreneurship- New Directions

Upcoming – TV Interview :Entrepreneurship in the Health Care Sector and Syndicated National Radio Interview: Entrepreneurship- New Directions

I have agreed to do a one hour TV interview on entrepreneurship in the health care sector. The interview will be scheduled for early January and follows my recent live TV interview discussing entrepreneurship on the weekly Upside Business Show on November 21st- the program was well received – copy of broadcast now available at http://www.ustream.tv/recorded/18671440 (click on Nov.21st show if needed)

While we see enormous challenges in today’s health care market, positive developments are emerging. One perspective, which I shared in my recent book ( Amazon at http://tinyurl.com/84texaf), is the pharmaceutical market includes two primary sectors—therapeutics (i.e., drugs) and diagnostics. Therapeutics is the pharmaceutical firms’ traditional business, reported to be about a $400 to $450 billion market.

Compare that to the diagnostics business, which includes several hundred companies, including many early stage entrepreneurial companies. Revenue estimates vary, but total diagnostic sector revenues are estimated at less than $30 billion, or less than 10 percent of a major pharmas traditional business. But diagnostics reduces health care costs and improves patient care, and many exciting developments are emerging providing the tools needed to improve early disease detection and wellness. Most important, we see entrepreneurial firms creating real excitement here. In the upcoming interview, I will share my vision on new directions I foresee and also invite one or more industry representatives to also share their insights.

I also accepted an invitation for an interview on a nationally syndicated NYC radio show to discuss new entrepreneurship directions and policies.

Stay tuned for dates and times – schedules to be firmed up shortly.

 

Tagged , , , , , , , , , ,